Current Report · Items 5.07, 9.01 · 8-K
Kyverna Therapeutics, Inc.
KYTXNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).…
Filed Jun 2, 2026Accepted Jun 2, 2026, 4:30 PM EDTCIK 1994702Accession 0001193125-26-253604
Company context
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).
Current securities
Disclosure sections
Items 5.07, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 60,530,293 shares of the Company’s common stock outstanding as of March 30, 2026, the record date for the Annual Meeting, 43,987,007 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 73% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.
At the Annual Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 13, 2026.
Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.
Proposal No. 1. To elect two Class II directors to hold office until the Company’s 2029 annual meeting of stockholders or until their successors are elected and qualified:
Director Nominee Votes For Votes Withheld Broker Non-Votes
──────────────────────────────────────────────────────────────────────────────
Ian Clark 31,505,902 3,255,231 9,225,874
Christi Shaw 34,528,865 232,268 9,225,874
As a result, the Company’s stockholders voted to elect Ian Clark and Christi Shaw as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified.
Proposal No. 2. To ratify the appointment by the Audit Committee of the Company’s Board of Directors of BDO USA, P.C., as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026:
Votes For Votes Against Abstentions
──────────────────────────────────────────────────
43,830,300 80,223 76,484
As a result, the Company’s stockholders voted to ratify the appointment of BDO USA, P.C., as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026.